Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria Vaccines
Reports summarize malaria vaccines research from J. Sacarlal and co-authors
March 19th, 2008
Investigators publish new data in the report 'Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.' "RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on the Plasmodium falciparum circumsporozoite surface antigen and is currently the most advanced malaria vaccine candidate in development. A proof of concept phase IIb trial of the RTS,S/AS02A in Mozambican children aged 1-4 years determined a vaccine efficacy against risk of clinical malaria of 35.3% (95% CI 21.6-46.6; p<0.0001) and against severe malaria of 48.6% (95% CI 12.3-71.0; p=0.02)," researchers in Mozambique report. "We evaluated the safety of the...
Source: Vaccine Weekly (2008-03-19)
|
